95120-45-9 Usage
Description
(2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol is a complex organic chemical compound characterized by the presence of a methoxy group, a nitroimidazole group, and a propan-2-ol group. It is defined by its molecular formula C6H10N4O4 and possesses a molecular weight of 198.16 g/mol. (2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol holds promise for its potential pharmacological properties, making it a candidate for drug development and pharmaceutical applications. Its unique chemical structure and properties render it a subject of interest for further research and possible utilization across various sectors, particularly in medicine and biotechnology.
Uses
Used in Pharmaceutical Development:
(2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol is utilized as a key component in the development of pharmaceutical products due to its potential pharmacological properties. Its unique structure allows it to be a candidate for the creation of new drugs that could address various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol serves as a subject of study for understanding its interactions with biological targets. This research could lead to the discovery of new mechanisms of action and the development of innovative therapeutic agents.
Used in Biotechnology Applications:
(2R)-1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol may also find use in biotechnology, where its specific chemical features could be employed for targeted drug delivery systems, diagnostic tools, or as part of bioactive molecules with specific functions in biotechnological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 95120-45-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,5,1,2 and 0 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 95120-45:
(7*9)+(6*5)+(5*1)+(4*2)+(3*0)+(2*4)+(1*5)=119
119 % 10 = 9
So 95120-45-9 is a valid CAS Registry Number.
95120-45-9Relevant articles and documents
Evaluation of (S)- and (R)-misonidazole as GPX inhibitors: Synthesis, characterization including circular dichroism and in vitro testing on bovine GPx-1
Wilde, Felix,Chamseddin, Chamseddin,Lemmerhirt, Heidi,Bednarski, Patrick J.,Jira, Thomas,Link, Andreas
, p. 153 - 160 (2014/03/21)
Racemic misonidazole, a radiosensitizer formally used in radiation therapy of cancer and to date still applied, was once reported to exhibit strong inhibitory effects on mouse glutathione peroxidases (GPX). This appeared to qualify misonidazole as a lead structure for the development of novel GPX inhibitors to cause oxidative stress in chemotherapy-resistant tumors. A unique feature of misonidazole as an inhibitor of GPX is the absence of a thiol functionality. Therefore, it was expected to selectively target inhibition devoid of promiscuous interactions with cations and sulfhydryl groups. We synthesized the isomers of misonidazole and analyzed the ability of chiroptical high-performance liquid chromatography (HPLC) to identify the particular enantiomers. Due to the chiral pool synthesis, the assignment of the correct configuration could be verified. Finally, we evaluated both isomers for their inhibitory activities on bovine erythrocyte GPx-1, which is 87% homologous to the human enzyme. Despite the previously reported inhibition of racemic misonidazole on the less homologous mouse GPx-1, we did not find any significant inhibitory activity on the bovine enzyme for either isomer. Though misonidazole appears unlikely to be an inhibitor of human GPx-1 activity, we still spotlight misonidazole as a promising fragment-like lead structure in general. The (S)- and (R)-isomers of misonidazole were synthesized and analyzed for their inhibitory activities on bovine erythrocyte GPx-1, which is 87% homologous to the human enzyme. Although misonidazole was found to be not likely to be an inhibitor of human GPx-1 activity, misonidazole is still spotlighted as a promising fragment-like lead structure in general.
